Search Result

Results for "

β-cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Amylases (1) Amylin Receptor (3) Antibiotic (2) Antifolate (1) Apoptosis (15) ATP-binding cassette (ABC) transporters (1) Autophagy (1) Bacterial (4) Calcium Channel (2) CD3 (1) CDK (1) CGRP Receptor (1) COX (2) Dipeptidyl Peptidase (5) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Drug Derivative (1) DYRK (6) EGFR (1) Endogenous Metabolite (9) Epigenetic Reader Domain (2) ERK (2) FLT3 (1) Fluorescent Dye (1) Free Fatty Acid Receptor (5) Fungal (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (1) GCGR (8) GLP Receptor (1) Glucokinase (6) Glycosidase (2) GlyT (3) GPR119 (4) GSK-3 (4) HDAC (1) Hippo (MST) (1) Histamine Receptor (1) HIV (1) HSP (2) IKK (1) Influenza Virus (1) Insulin Receptor (5) Interleukin Related (2) Isotope-Labeled Compounds (8) Lipoxygenase (1) mAChR (1) Molecular Glues (1) mRNA (2) NF-κB (3) P2Y Receptor (1) Parasite (2) Phospholipase (2) PI3K (1) PKC (3) Potassium Channel (30) Prostaglandin Receptor (1) PTHR (1) Ras (2) Reactive Oxygen Species (ROS) (4) Reference Standards (11) STAT (2) TNF Receptor (1) TRP Channel (1) VDAC (1) Wnt (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (12) Endocrinology (3) Infection (7) Inflammation/Immunology (11) Metabolic Disease (105) Neurological Disease (11)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	mRNA (2)

128

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109030

Dorzagliatin 2 Publications Verification HMS5552	Glucokinase	Metabolic Disease
Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-109030R

Dorzagliatin (Standard) HMS5552 (Standard)	Reference Standards Glucokinase	Metabolic Disease
Dorzagliatin (Standard) is the analytical standard of Dorzagliatin. This product is intended for research and analytical applications. Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes .

HY-B1021

Vincamine 1 Publications Verification	Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-105063

DiaPep277	HSP	Metabolic Disease Inflammation/Immunology
DiaPep277 is a 24 amino acid peptide derived from positions 437-460 in HSP60. DiaPep277 arrests the progression of β-cell destruction in NOD mice. DiaPep277 has an immune modulatory effect on diabetogenic T cells in animal models of diabetes .

HY-N3419

Kobusone	Others	Metabolic Disease
Kobusone is a natural compound isolated form Aquilaria sinensis. kobusone can stimulate islet β-cell replication in vivo, and has the potential to be used in diabetic study .

HY-120711

BRD0476 ML187	Apoptosis	Metabolic Disease
BRD0476 is an inhibitor of pancreatic β-cell apoptosis with an EC₅₀ value of 0.78 μM and a maximal inhibitory activity of 99%. BRD0476 can be used in diabetes-related research .

HY-N15196

Andrographolide-lipoic acid	NF-κB	Metabolic Disease
Andrographolide-lipoic acid is an Andrographolide (HY-N0191) analogue, which is formed by the coupling of Andrographolide and Lipoic acid (HY-18733). Andrographolide-lipoic acid inhibits NF-κB and has anti-diabetic and β-cell protective activities .

HY-129736A

P32/98	Dipeptidyl Peptidase	Metabolic Disease
P32/98 a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .

HY-B1021R

Vincamine (Standard)	Reference Standards Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-129736

P32/98 hemifumarate	Dipeptidyl Peptidase	Metabolic Disease
P32/98 hemifumarateis a potent inhibitor of dipeptidyl peptidase IV with a K_i value of 130 nM. P32/98 hemifumarate improves glucose tolerance, insulin sensitivity and β-cell responsiveness in fatty Zucker rat model .

HY-B2028

Propargite	Parasite	Infection
Propargite is a pesticide used to kill mites. Propargite induces β-cell necrosis preceded by DNA damage. Propargite induces MIN6 cell death with an IC₅₀?of?1?μM . Propargite is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B2028R

Propargite (Standard)	Reference Standards Parasite	Infection
Propargite (Standard) is the analytical standard of Propargite. This product is intended for research and analytical applications. Propargite is a pesticide used to kill mites. Propargite induces β-cell necrosis preceded by DNA damage. Propargite induces MIN6 cell death with an IC50 of 1 μM . Propargite is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-138990

GK563	Phospholipase Apoptosis	Inflammation/Immunology
GK563 is a selective Ca ²⁺-independent phospholipase A₂ (GVIA iPLA₂) inhibitor with an IC₅₀ value of 1 nM. GK563 is 22000 times more active against GVIA iPLA₂ than GIVA cPLA₂. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-142295

GNF2133 1 Publications Verification	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .

HY-142295A

GNF2133 hydrochloride	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .

HY-117049

Leucettine L41 1 Publications Verification	DYRK CDK GSK-3 Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
Leucettine L41 is a potent inhibitor of dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) and CDC-like kinases (CLKs). Leucettine L41 can also inhibit GSK-3 singnaling. Leucettine L41 can inhibit cell apoptosis and ROS production. Leucettine L41 can promote β-cell cell cycle progression, cell proliferation and increase insulin secretion. Leucettine L41 can be used for the researches of neurological disease and metabolic disease, such as Alzheimer’s disease (AD) and diabetes .

HY-111310

ML351 1 Publications Verification	Lipoxygenase	Neurological Disease Metabolic Disease
ML351 is a potent and highly specific 15-LOX-1 inhibitor with an IC₅₀ of 200 nM. ML351 shows excellent selectivity (>250-fold) versus the related isozymes, 5-LOX, platelet 12-LOX, 15-LOX-2, ovine COX-1, and human COX-2 . ML351 prevents dysglycemia and reduces β-cell oxidative stress in nonobese diabetic mouse model of T1D .

HY-15564

AR 231453 2 Publications Verification	GPR119	Metabolic Disease
AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-139792

Besigliptin tosylate SHR117887	Endogenous Metabolite	Metabolic Disease
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .

HY-147502

Vin-C01	Apoptosis	Cardiovascular Disease
Vin-C01 is a potent pancreatic β-cells protective agent with an EC₅₀ of 0.22 μM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research .

HY-147503

Vin-F03	Apoptosis	Cardiovascular Disease
Vin-F03 is a potent pancreatic β-cells protective agent with an EC₅₀ of 0.27 μM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ (HY-13753)-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research .

HY-147760

Dyrk1A-IN-2	DYRK	Metabolic Disease
Dyrk1A-IN-2 (Compound 63) is a DYRK1A inhibitor with an EC₅₀ of 37 nM. Dyrk1A-IN-2 exhibits highly potent human β-cell replication-promoting activity and low cytotoxicity .

HY-159496

Dyrk1A-IN-10	DYRK	Metabolic Disease
Dyrk1A-IN-10 (compound B4) is a DYRK1A inhibitor with antidiabetic activity. Dyrk1A-IN-10 can promote pancreatic β-cell proliferation, increase insulin secretion, and lower blood sugar .

HY-176745

SW016789	VDAC	Metabolic Disease Endocrinology
SW016789 is a hypersecretion-inducer targeting VDAC1. SW016789 can induce insulin hypersecretion and Ca ²⁺ influx in β-cells directly. SW016789 induces a transient endoplasmic reticulum stress response (ER stress), but does not cause beta cell death. SW016789 has reversible and non-apoptotic characteristics. SW016789 can be used for the study of Diabetes mellitus type 2 (T2DM) β-cell dysfunction .

HY-15564R

AR 231453 (Standard)	GPR119	Metabolic Disease
AR 231453 (Standard) is the analytical standard of AR 231453. This product is intended for research and analytical applications. AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s .

HY-B0422

Nateglinide A4166; Senaglinide	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-B0422S

Nateglinide-d5 A4166 d₅; Senaglinide d₅	Potassium Channel Dipeptidyl Peptidase	Metabolic Disease
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-129492

GNF4877 1 Publications Verification	DYRK GSK-3	Metabolic Disease
GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC₅₀s of 6 nM and 16 nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC₅₀ of 0.66 μM for mouse β (R7T1) cells) .

HY-B0422R

Nateglinide (Standard) A4166 (Standard); Senaglinide (Standard)	Potassium Channel Dipeptidyl Peptidase Reference Standards	Metabolic Disease
Nateglinide (Standard) is the analytical standard of Nateglinide. This product is intended for research and analytical applications. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K ⁺ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus .

HY-167931

Cinnamohydrazide	Drug Derivative	Metabolic Disease
Cinnamohydrazide, an unsaturated carboxylic acid derivative, serves as a precursor to aspartame through enzyme-mediated amination to phenylalanine. This compound may offer potential benefits in the prevention and treatment of diabetes by facilitating insulin secretion, enhancing pancreatic β-cell function, inhibiting hepatic gluconeogenesis, promoting glucose uptake, amplifying insulin signaling pathways, delaying carbohydrate digestion and glucose absorption, and reducing protein glycation and insulin fibrillation.

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-16673

PSN632408	GPR119	Metabolic Disease
PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC₅₀=5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-124424

VU0071063	Potassium Channel	Others Neurological Disease
VU0071063 is a potent and specific Kir6.2/SUR1 opener (EC₅₀=7.44 μM) and can be used for investigating Kir6.2/SUR1 expressed in the pancreas and brain. VU0071063 inhibits insulin secretion by inducing hyperpolarization of β-cell membrane potential. VU0071063 chemotype has a very steep structure-activity relationships .

HY-19618

BRD3308 1 Publications Verification	HDAC HIV Apoptosis	Infection Metabolic Disease
BRD3308 is a highly selective HDAC3 inhibitor with an IC₅₀ of 54 nM. BRD3308 is 23-fold selectivity for HDAC3 over HDAC1 (IC₅₀ of 1.26 μM) or HDAC2 (IC₅₀ of 1.34 μM). BRD3308 suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release. BRD3308 activates HIV-1 transcription and disrupts HIV-1 latency .

HY-W010649

Isoxazole	HSP Epigenetic Reader Domain ATP-binding cassette (ABC) transporters Bacterial Fungal Antibiotic	Infection Metabolic Disease Inflammation/Immunology Cancer
Isoxazole is a member of the five-membered heterocycle drug scaffold. Isoxazole has been used as a BET bromodomain inhibitor and can improve β-cell function in a diabetic mouse model. Isoxazole and its derivatives exhibit broad biological activities (such as antimicrobial, antibacterial, antifungal, antiviral, anticancer, anti-inflammatory, immunomodulatory, analgesic, anti-tuberculosis, and anti-diabetic effects). For example, the bicyclic Isoxazole can act as an HSP90 inhibitor, and the tricyclic Isoxazole is promising as a selective multidrug resistance protein (MRP1) inhibitor .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-W015229R

3-Indolepropionic acid (Standard) Indole-3-propionic acid (Standard); 3-IPA (Standard)	Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS)	Neurological Disease Metabolic Disease
3-Indolepropionic acid (Standard) is the analytical standard of 3-Indolepropionic acid. This product is intended for research and analytical applications. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. In Vitro: 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease . 3-Indolepropionic acid is a more potent scavenger of hydroxyl radicals than melatonin. Similar to melatonin but unlike other antioxidants, 3-Indolepropionic acid scavenges radicals without subsequently generating reactive and pro-oxidant intermediate compounds . It is also suggested that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of type 2 diabetes (T2D) that may mediate its protective effect by preservation of β-cell function .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-B0753

Gliclazide 4 Publications Verification S1702; SE1702	Potassium Channel	Cardiovascular Disease
Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM. Gliclazide is used as an antidiabetic .

HY-P4813

Preptin (rat)	DNA/RNA Synthesis	Metabolic Disease
Preptin, an osteogenic peptide product of the pancreatic beta-cell, corresponds to Asp ⁶⁹-Leu ¹⁰² of pro-IGF-II .

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P3101

GLP-1(28-36)amide	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .

HY-119322R

Tifenazoxide (Standard)	Potassium Channel	Metabolic Disease
Tifenazoxide (Standard) is the analytical standard of Tifenazoxide. This product is intended for research and analytical applications. Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective KATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .

HY-P3101A

GLP-1(28-36)amide TFA	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .

HY-119322

Tifenazoxide NN414	Potassium Channel	Metabolic Disease
Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ^ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .

HY-174585

Human MAFA mRNA	mRNA	Metabolic Disease
Human MAFA mRNA encodes the human MAF bZIP transcription factor A (MAFA) protein, a transcription factor that regulates pancreatic beta cell-specific expression of the insulin gene.

HY-P1156

Insulin(cattle) 10+ Cited Publications	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

968 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 968 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-105063

DiaPep277	HSP	Metabolic Disease Inflammation/Immunology
DiaPep277 is a 24 amino acid peptide derived from positions 437-460 in HSP60. DiaPep277 arrests the progression of β-cell destruction in NOD mice. DiaPep277 has an immune modulatory effect on diabetogenic T cells in animal models of diabetes .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P10018

Bamadutide SAR425899	GLP Receptor GCGR	Metabolic Disease
Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P1475

C-Peptide, dog C-Peptide (dog)	Peptides	Metabolic Disease
C-Peptide, dog is a component of proinsulin, released from pancreatic beta cells into blood together with insulin.

HY-P5390

GIP, rat	Peptides	Others
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)

HY-P4813

Preptin (rat)	DNA/RNA Synthesis	Metabolic Disease
Preptin, an osteogenic peptide product of the pancreatic beta-cell, corresponds to Asp ⁶⁹-Leu ¹⁰² of pro-IGF-II .

HY-P3101

GLP-1(28-36)amide	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects .

HY-P3101A

GLP-1(28-36)amide TFA	GCGR	Cardiovascular Disease Metabolic Disease
GLP-1(28-36)amide TFA, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide TFA is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide TFA has anti-diabetic and cardioprotection effects .

HY-P1156

Insulin(cattle) Maximum Cited Publications 11 Publications Verification	Insulin Receptor	Metabolic Disease Endocrinology
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.

HY-P3864

Pancreastatin (37-52), human	Insulin Receptor	Metabolic Disease
Pancreastatin (37-52), human is a pancreastatin fragment. Pancreastatin a CgA-derived peptide (CgA residues 250–301) with biological activity, inhibited the releasing of insulin by islet beta cells .

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

HY-P5796

FS-2	Calcium Channel	Neurological Disease
FS-2 is a potent and specific L-type Ca_V channel inhibitor. FS-2 inhibits high K ⁺ or glucose induced L-type Ca ²⁺ influx in RIN beta cells .

HY-P10305

Visepegenatide PB-119	Insulin Receptor	Metabolic Disease
PB-119 is a PEGylated Exenatide. PB-119 decreases glycemic levels by improving beta-cell function and insulin resistance. PB-119 can be used for research of type 2 diabetes .

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-106288

Human PTHrP-(1-36)	PTHR	Cancer
Human PTHrP-(1-36) is a secretory form of PTHrP with anticalciuric effects. Human PTHrP-(1-36) enhances beta cell function and proliferation. Human PTHrP-(1-36) can be used in the research of humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism .

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-13443F1

Exendin-4, Cy5 labeled TFA	GCGR Fluorescent Dye	Metabolic Disease
Exendin-4, Cy5 labeled TFA is a Cy5 labeled Exendin 4 (HY-13443). Exendin-4, Cy5 labeled TFA can be used as in vivo β cell tracer. Exendin 4 is a long-acting GLP-1 receptor agonist .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-P2501

Amylin (8-37), human	Amylin Receptor	Metabolic Disease
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .

HY-P10622

SHLP-3	Apoptosis Reactive Oxygen Species (ROS)	Metabolic Disease Cancer
SHLP-3 is a mitochondrial derived peptide encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-3 increases cell viability and reduces apoptosis in insulinoma NIT-1β cells and human prostate cancer 22Rv1 cells. SHLP-3 increases mitochondrial function and exerts cytoprotective effects by increasing mitochondrial oxygen consumption rate (OCR), cellular ATP and reducing the ability to produce ROS. SHLP-3 can be used in the study of diabetes and cancer .

Cat. No.	Product Name	Target	Research Area

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1021

Vincamine 1 Publications Verification	Apocynaceae Cardiovascular Disease Alkaloids Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-W015229R

3-Indolepropionic acid (Standard) Indole-3-propionic acid (Standard); 3-IPA (Standard)	Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite Reactive Oxygen Species (ROS)
3-Indolepropionic acid (Standard) is the analytical standard of 3-Indolepropionic acid. This product is intended for research and analytical applications. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease. In Vitro: 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease . 3-Indolepropionic acid is a more potent scavenger of hydroxyl radicals than melatonin. Similar to melatonin but unlike other antioxidants, 3-Indolepropionic acid scavenges radicals without subsequently generating reactive and pro-oxidant intermediate compounds . It is also suggested that indolepropionic acid, a gut microbiota-produced metabolite, is a potential biomarker for the development of type 2 diabetes (T2D) that may mediate its protective effect by preservation of β-cell function .

HY-N10587

Catechin 7-O-β-D-glucopyranoside	other families Classification of Application Fields Phenols Plants Inflammation/Immunology Disease Research Fields Pteris multifida Poir. Food Research	Others
Catechin 7-O-beta-D-glucopyranoside is an orally active natural product found in Ulmus davidiana and Paeonia obovata. Catechin 7-O-β-D-glucopyranoside shows antioxidant and anti-inflammatory activities, and attenuates mitochondrial dysfunction. Catechin 7-O-beta-D-glucopyranoside can be used in intestinal inflammatory disease research .

HY-13753

Streptozotocin Maximum Cited Publications 112 Publications Verification Streptozocin; NSC-85998; U 9889	Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Mammalian Cell Culture Disease Research Anticancer Disease Research Fields Other Antibiotics Cancer	DNA/RNA Synthesis DNA Alkylator/Crosslinker Autophagy Bacterial Antibiotic Apoptosis
Streptozotocin (Streptozocin; STZ) is an antibiotic widely used in experimental animal models of induced diabetes. Streptozotocin enters B cells via the glucose transporter (GLUT2) and causes the alkylation of DNA ( DNA-methylating ). Streptozotocin can induce the apoptosis of β cells .

HY-N0466

Rebaudioside A	Trifolium hybridum L. Classification of Application Fields Terpenoids Source classification Other Diseases Diterpenoids Plants Compositae Endogenous metabolite Disease Research Fields Sweeteners Food Research	Glycosidase Endogenous Metabolite Potassium Channel
Rebaudioside A is a steviol glycoside with high sweetness potency and is a potent α-glucosidase inhibitor with an IC₅₀ value of 35.01 ug/mL. Rebaudioside A directly stimulates insulin secretion from pancreatic beta cells via inhibition of ATP-sensitive K ⁺-channels .

HY-N3419

Kobusone	Natural Products Animals Source classification	Others
Kobusone is a natural compound isolated form Aquilaria sinensis. kobusone can stimulate islet β-cell replication in vivo, and has the potential to be used in diabetic study .

HY-N15196

Andrographolide-lipoic acid	Natural Products Andrographis paniculata (Burm. F.) Nees Acanthaceae Source classification Plants	NF-κB
Andrographolide-lipoic acid is an Andrographolide (HY-N0191) analogue, which is formed by the coupling of Andrographolide and Lipoic acid (HY-18733). Andrographolide-lipoic acid inhibits NF-κB and has anti-diabetic and β-cell protective activities .

HY-B1021R

Vincamine (Standard)	Apocynaceae Alkaloids Source classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don	Reference Standards Free Fatty Acid Receptor
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-N9363

Corymbiferin	other families Xanthones Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Others
Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .

HY-N7729

Sekikaic acid	Microorganisms Ketones, Aldehydes, Acids Source classification	Amylases Glycosidase
Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .

HY-129297

CMPF	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .

HY-113202

Stearoylcarnitine 1 Publications Verification	Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite PKC GlyT
Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Anthocyans Flavonoids Classification of Application Fields Source classification Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields	Insulin Receptor
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

Cat. No.	Product Name	Chemical Structure

HY-B0422S

Nateglinide-d5
Nateglinide-d₅ is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells. Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2].

HY-B0753S

Gliclazide-d4
Gliclazide-d₄ (S1702 D₄) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM. Gliclazide is used as an antidiabetic .

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans .

HY-W723322

Ethyl tosylcarbamate-d7
Ethyl tosylcarbamate-d₇ is the deuterium labeled Ethyl tosylcarbamate (HY-135337). Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877) . Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC₅₀ of 184 nM .

HY-W703629

Acetohexamide-d11
Acetohexamide-d₁₁ is the deuterium labeled Acetohexamide (HY-B0881). Acetohexamide is a first-generation sulfonylurea agent used in research related to type 2 diabetes; it stimulates the pancreas to secrete insulin.Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas .

HY-B0682S2

Mitiglinide-d5 calcium
Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-B0682S1

(2R)-Mitiglinide-d5 calcium
(2R)-Mitiglinide-d₅ (calcium) is deuterium labeled Mitiglinide. Mitiglinide (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide can be used for the research of type 2 diabetes .

HY-B0682S

Mitiglinide-d8 calcium hydrate

Mitiglinide-d₈ calcium hydrate (KAD-1229-d₈) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-W777434

Mitiglinide calcium hydrate-d8

Mitiglinide (calcium hydrate)-d₈ is the deuterium labeled Mitiglinide (calcium hydrate) (HY-B0682A). Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes .

HY-113202S

Stearoyl-L-carnitine-d3

Stearoyl-L-carnitine-d₃ is the deuterium labeled Stearoylcarnitine. Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2 .

HY-113202S1

Stearoyl-L-carnitine-d9 chloride

Stearoyl-L-carnitine-d9 chloride is the deuterium labeled Stearoyl-L-carnitine chloride. Stearoyl-L-carnitine chloride, a fatty ester lipid molecule, is an endogenous metabolite. Stearoyl-L-carnitine chloride can be used as PKC inhibitor. Stearoyl-L-carnitine chloride accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoyl-L-carnitine chloride inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoyl-L-carnitine chloride acts as a metabolomics biomarker for Parkinson’s disease. Stearoyl-L-carnitine chloride is a less potent inhibitor of GlyT2 .

Cat. No.	Product Name		Classification